Latest videos

Home
Articles

Mesothelioma Autopsy - Why Is An Autopsy Needed In An Asbestos Case? administrator 1 Views • 2 years ago

Mesothelioma Autopsy
➡️ http://MesotheliomaUSA.net

Reporting the Death.

If a person dies from mesothelioma or lung cancer at home then usually their GP reports the death to the Coroner. If the person dies in a hospital or hospice then the treating medical staff will report the death.

Initial contact with the Coroner’s Officer.

The Coroner’s Officer, who assists the Coroner, is usually the point of contact for family members. The Officer will ask about the person’s work history and exposure to asbestos dust. If the person was bringing or had brought a mesothelioma or lung cancer claim then you should give the Coroner’s Officer the details of your asbestos solicitor who can then provide the person’s work history and asbestos exposure evidence. This will assist and help progress the Coroner’s investigation.

Post Mortem Examination.

The Coroner might decide that a post mortem examination is necessary. Sometimes, lung tissue samples are taken and sent to a laboratory for further analysis to determine the part played by asbestos in the person’s death.

In a mesothelioma claim the Coroner might decide a post mortem is not needed if the person had a biopsy confirming the diagnosis during their lifetime.

Usually in lung cancer cases a post mortem is carried out. Lung tissue samples are taken and analysed using a special microscope to assess the level of asbestos fibres in the lungs. The amount of fibres could help establish that the lung cancer was asbestos related.

The pathologist carries out the post mortem examination within a few days of the death and prepares a report for the Coroner. After the examination the funeral can take place.

Inquest opened and adjourned.

The Coroner will open and adjourn the inquest so that the documents and evidence needed by the Coroner can be gathered.

Once the investigations have been completed the inquest will be re-opened.

The Coroner will issue an interim death certificate shortly after the death.

Inquest concluded.

The Coroner might decide to conclude the investigation or inquest without a hearing. The Coroner will provide his/her verdict as to the cause of the person’s death in writing.

Sometimes, the Coroner does this at a final hearing.

At this hearing the Coroner considers all the evidence including the post mortem report and evidence of the person’s work history and exposure to asbestos dust.

Family members can attend and ask questions of anyone called to give evidence.

The pathologist who carried out the post mortem examination might attend the hearing to give evidence to the Coroner and answer any questions the Coroner, we or family members might have.

Our specialist asbestos solicitors will also attend the Inquest to provide support to the grieving family members and to ask any questions that haven’t been answered.

Once the Coroner has considered and heard all the evidence and answered any questions, he/she gives their ‘verdict’ for the cause of the person’s death.

In mesothelioma or lung cancer cases the court may conclude the death was due to an industrial disease.

If a mesothelioma claim or lung cancer claim is being brought then this conclusion can be helpful. However, if the Coroner does not reach this conclusion then it does not mean that you cannot bring a mesothelioma claim or lung cancer claim.

After the inquest is concluded the Coroner will arrange for the death to be registered and a final death certificate is then issued.

Lung Tissue Samples.

After the Inquest has concluded, the Coroner’s officer might ask family members what to do with any lung tissue samples taken from the person. The samples could be retained, disposed of respectfully and sensitively by the hospital, donated for medical research or released to you for burial or cremation.

You should speak to one of our specialist asbestos solicitors before making any decision because in some asbestos claims, such as lung cancer claims, it is advisable that the lung tissue samples be retained until the claim is concluded. If a mesothelioma claim or lung cancer claim is being brought or will be brought at a future date your opponents might argue that you withheld vital evidence by not retaining the lung tissue samples and might persuade the court that you should not be allowed to bring a claim for that reason.

Mesothelioma Autopsy - Why Is An Autopsy Needed In An Asbestos Case?
https://www.youtube.com/watch?v=bjUHDFx3g9Y
https://www.youtube.com/channe....l/UCOVJwa1zpdmoeq2db

#ismesotheliomaadeathsentence #mesotheliomaautopsy #autopsyformesothelioma #canyoudiefrommesothelioma #howdoyoudiewithmesothelioma #howlongdoesittakeformesotheliomatokillyou

🔗 https://www.asbestoslawpartner....ship.co.uk/mesotheli

Nivolumab/Ipilimumab Approved In Europe For Frontline Unresectable Malignant Pleural Mesothelioma administrator 17 Views • 2 years ago

Nivolumab And Ipilimumab Approved In Europe For Frontline Unresectable Malignant Pleural Mesothelioma
➡️ http://MesotheliomaUSA.net

The European Commission has approved the dual immunotherapy combination of nivolumab and ipilimumab for use in the frontline treatment of adults with unresectable malignant pleural mesothelioma.

The regulatory decision was based on findings from the phase 3 CheckMate-743 trial (NCT02899299), which showed that the doublet resulted in a 26% reduction in the risk of death compared with platinum-based, standard-of-care chemotherapy (HR, 0.74; 96.6% CI, 0.60-0.91; P = .002). The median OS with the immunotherapy regimen was 18.1 months (95% CI, 16.8-21.4) vs 14.1 months (95% CI, 12.4-16.2) with chemotherapy, meeting the primary end point of the trial. The 2-year OS rates in the investigative and combination arms were 41% and 27%, respectively.

This is the first positive phase 3 trial of an immunotherapy in the frontline treatment of malignant pleural mesothelioma, according to Bristol Myers Squibb.

“After many years of limited progress in the treatment of malignant mesothelioma, we saw an important clinical benefit for patients with nivolumab plus ipilimumab in the CheckMate-743 trial,” Paul Baas, MD, PhD, of the Department of Thoracic Oncology at the Netherlands Cancer Institute and the University of Leiden, stated in a press release. “With the EC approval of this dual immunotherapy combination, patients and doctors will now have a new treatment option that has shown significant improvements in survival to manage this resistant disease.”

In the open-label, multicenter phase 3 CheckMate-743 trial, investigators examined nivolumab plus ipilimumab vs chemotherapy, which was either pemetrexed and cisplatin or carboplatin, in 605 patients with previously untreated malignant pleural mesothelioma.

Notably, patients who had interstitial lung disease, active autoimmune disease, any conditions that required systemic immunosuppression, or active brain metastases, were not eligible for enrollment. Participants were stratified based on histology, epithelial vs non-epithelial disease, and gender.

Study participants were randomized to receive either nivolumab at 3 mg/kg biweekly plus ipilimumab at 1 mg/kg every 6 weeks (n = 303), or cisplatin at 75 mg/m2 or carboplatin AUC 5 plus pemetrexed at 500 mg/m2 in 21-day treatment cycles for 6 cycles. Patients continued to receive treatment until progressive disease or intolerable toxicity; if in the doublet immunotherapy arm, they received up until 24 months.

The primary end point of the trial was OS in all randomized patients, while other key end points included progression-free survival (PFS), objective response rate (ORR), and duration of response (DOR) per blinded independent central review and RECIST criteria. Other exploratory end points comprised safety, pharmacokinetics, immunogenicity, and patient-reported outcomes.

Additional data from the trial showed that the median PFS with nivolumab plus ipilimumab was shorter than that observed with chemotherapy, at 6.8 months vs 7.2 months, respectively (HR, 1.00; 95% CI, 0.82-1.21). However, the 1-year PFS rates in the investigative and control arms were 30% and 16%, respectively, while the 2-year PFS rates were 24% and 7%, respectively.

The ORRs between the investigative and control arms were similar, at 40% (95% CI, 34.1%-45.4%) and 43% (95% CI, 37.1%-48.5%), respectively. Moreover, the median DOR achieved with the doublet was 11.0 months (95% CI, 8.1-16.5) vs 6.7 months with chemotherapy (95% CI, 5.3-7.1). Thirty-two percent of the responders who received the immunotherapy combination experienced a response that continued at 2 years vs just 8% who received the chemotherapy. The median time to response was 2.7 months with the doublet and 2.5 months with the chemotherapy.

Additional data presented during the 2020 International Association for the Study of Lung Cancer’s World Conference on Lung Cancer Virtual Presidential Symposium showed that the 1-year OS rate with nivolumab plus ipilimumab was 68% vs 58% with chemotherapy. The 2-year OS rates in the investigative and control arms were 41% and 27%, respectively.

Notably, the survival benefit of the dual immunotherapy regimen was observed across all prespecified subgroups, irrespective of epithelioid disease or PD-L1 expression.

Regarding safety, nivolumab plus ipilimumab was determined to be manageable using established adverse effect management protocols.

Nivolumab And Ipilimumab Approved In Europe For Frontline Unresectable Malignant Pleural Mesothelioma
https://www.youtube.com/watch?v=DA_yr5WbOM8
https://www.youtube.com/channe....l/UCOVJwa1zpdmoeq2db

#nivolumab #opdivo #ipilimumab #yervoy #malignant #pleuralmesothelioma #europeancommission #immunotherapy

🔗 https://www.onclive.com/view/n....ivolumab-ipilimumab-

MESOTHELIOMA AVERAGE AGE AT DIAGNOSIS - MESOTHELIOMA SURVIVAL RATE administrator 2 Views • 2 years ago

MESOTHELIOMA AVERAGE AGE AT DIAGNOSIS
➡️ http://MesotheliomaUSA.net

Between 1999 and 2015, there were more than 54,000 documented cases of mesothelioma in the United States. While mesothelioma cancer is rare in relation to many other types of cancer, it has very real consequences for Americans in all walks of life. In fact, many people wonder if they’re part of an age group that is at risk for the disease.

What Is the Average Age at Diagnosis?

The average age of diagnosis for those with mesothelioma is 69 years old. Patients between 80 and 84 experience the highest incidence of mesothelioma, closely followed by the 85-89 age group.

Why Is Mesothelioma Diagnosed Later in Life?

Generally, mesothelioma surfaces later in life due to its long latency period. The condition is notoriously difficult to diagnose because its symptoms don’t appear right away. As the disease progresses, the symptoms that do surface, such as dry coughing, wheezing, and chest pain, are easily mistakable for other illnesses. That’s why it’s important to get tested for mesothelioma if you suspect you may have been exposed to asbestos — the only known cause.

Who Should Be Evaluated for Mesothelioma?

If you notice symptoms of mesothelioma, see a doctor for evaluation right away. If you’ve worked in any of the following industries, you may be at an increased risk for the disease.

Construction: Construction workers were routinely exposed to asbestos products throughout the 20th century. Many of today’s roofing and flooring materials are still made with asbestos.
Firefighters: When fire damages asbestos materials, especially in older buildings, those materials can become airborne.
Industrial Workers: Mechanics, chemical workers, insulators, and machine operators were among the workers most routinely exposed to asbestos in the last century.
Miners: Although mining for asbestos in the U.S. ended in 2002, many miners have since been exposed to it, as minerals including talc are contaminated with asbestos.

Schedule a Case Evaluation With a Mesothelioma Attorney

Those diagnosed with mesothelioma are victims, regardless of their age. If you or someone you love has been diagnosed with this form of cancer, hiring the right legal counsel can make all the difference. The asbestos attorneys at Morgan & Morgan are ready to fight for the compensation and justice you deserve, and hold any responsible parties accountable. We understand what you’re going through and want to be by your side during these trying times. We treat every client like family and extend them the same compassion we would to our own loved ones, ensuring the best possible service. Compensation grants victims and their loved ones the peace of mind necessary to focus on what’s most important. Victims can receive significant compensation from their employer or an asbestos trust fund. Join the Morgan & Morgan family and discover what we can do for you — schedule a free case evaluation with one of our attorneys now.

MESOTHELIOMA AVERAGE AGE AT DIAGNOSIS - MESOTHELIOMA SURVIVAL RATE
https://www.youtube.com/watch?v=QnvSv1hTyWk
https://www.youtube.com/channe....l/UC36qCuQ_tAGvvNv5T

#mesotheliomaaverageageatdiagnosis #mesotheliomasurvivalrate #mesotheliomasurvival

🔗 https://www.forthepeople.com/m....esothelioma-attorney

Mesothelioma Pathology - Incidence of Mesothelioma administrator 4 Views • 2 years ago

Mesothelioma Pathology
➡️ http://MesotheliomaUSA.net

Incidence of mesothelioma.

Mesothelioma is a malignant tumor that originates in the pleura, peritoneum, pericardium and tunica vaginalis, all locations where a lining of normal mesothelial cell is present. According to the official data of Ministry of Health, Labor and Welfare in Japan, the number of death due to mesothelioma was 500 in 1995, increasing gradually to 953 in 2004. This increase appears to parallel the increase of the amount of asbestos imported into Japan between 1960 and 1975, given that the latent period from the beginning of exposure to asbestos and an initial diagnosis of mesothelioma is approximately 40 years.

More detailed examination of the 878 patients who officially died from mesothelioma in 2003 reveals that the male:female ratio was almost 3:1 and that the peak of age of patients was 60+ in males and 70+ in females. The location of the mesothelioma was in the pleura in 84% of the cases, in the peritoneum in 12% and in the pericardium in 1%; there were not cases of mesothelioma in the tunica vaginalis. A larger proportion of females had mesothelioma in the peritoneum and pericardium than in the pleura.

General findings on mesothelioma.

Mesothelioma can be roughly classified into localized and diffuse types, with the incidence of the latter being much higher than that of the former. The localized form of mesothelioma was more frequently diagnosed in the past; however, most of the localized forms are currently diagnosed as a solitary fibrous tumor, which is a separate entity from mesothelioma based on immunohistochemical phenotyping (positive for CD34, a marker of primitive endothelial cell) and has no relation to asbestos exposure.

At the early stage of pleural mesothelioma, small nodules are found in the parietal pleura (not in the visceral pleura) that eventually extend along the pleural surface. Eventually, parietal and visceral pleurae show adhesion, and the tumor encloses the entire lung parenchyma. Very few cases of peritoneal mesothelioma have been reported at the early stage and, consequently, little is known in terms of pathology and disease progression during the early stage. Most of peritoneal mesothelioma is found as a diffusely extensive tumor involving intestinal serosa or a large tumor located at the omentum or mesentery.

Following the initial diagnosis of mesothelioma, it is important to confirm the location of the tumor and its gross findings before histological examination. In the case of a pleural mesothelioma, a tumor in the lung parenchyma suggests lung cancer with a pleural extension. In females with peritoneal extension, the ovary should be carefully examined as the primary site of the tumor because the differential diagnosis between ovarian cancer and peritoneal mesothelioma is difficult and can only be made on the basis of histological analyses.

Histology of mesothelioma.

Histological classification of mesothelioma is shown. There are three major types—epithelioid type, sarcomatoid type and biphasic type—and the proportion of each is approximately 60, 20 and 20%, respectively. The desmoplastic type is rare (probably 1–2%), and special variants only appear sporadically (several percentages). However, the proportion of each histological type varies among the reports because of the large variety of histological analyses used.

Differential diagnosis.

It is important to remember that there are many diseases to be differentiated when making a pathological diagnosis and that the tissue to be differentiated varies in terms of histological type. Epithelioid types must be differentiated from lung adenocarcinoma for pleural mesothelioma, ovarian serous papillary adenocarcinoma or peritoneal serous carcinoma for peritoneal mesothelioma. In terms of sarcomatoid types, sarcoma originating in the chest wall, lung, pleura, abdominal wall, peritoneum and intestine must be excluded. Sarcomatoid carcinoma (spindle cell sarcoma or pleomorphic carcinoma) of the lung is very difficult to differentiate from sarcomatoid pleural mesothelioma. In terms of the biphasic type, carcinosarcoma or pulmonary blastoma of the lung, biphasic synovial sarcoma of the pleural mesothelioma and carcinosarcoma of the female genital organs must be differentiated from their peritoneal counterpart. The desmoplastic type has a similar histology to fibrous pleuritis, and the differential diagnosis is very difficult, particularly if only a small biopsy specimen is available.

Mesothelioma Pathology - Incidence of Mesothelioma
https://www.youtube.com/watch?v=rS593tB4Z-4
https://www.youtube.com/channe....l/UCPhQmbwbQCspqO0e1

#mesotheliomapathology #mesotheliomapathologyreport #mesotheliomapathologyreview #mesotheliomapathologyslideshare #mesotheliomapathologystains

🔗 https://www.ncbi.nlm.nih.gov/p....mc/articles/PMC26982

Showing 3158 out of 3159

Please note that if you are under 18, you won't be able to access this site.

Latest videos

Language